Immune signatures measured at baseline and immediately prior to vaccination may predict
the immune response to vaccination. Such pre-vaccine assessment might allow not only …

Nearly 2.3 million individuals worldwide are coinfected with human immunodeficiency virus
(HIV) and hepatitis C virus (HCV). Odds of HCV infection are six times higher in people living …

HIV elite controllers maintain a population of CD4+ T cells endowed with high avidity for Gag
antigens and potent effector functions. How these HIV-specific cells avoid infection and …

Toll-like receptor 7 (TLR7) agonists, in combination with other therapies, can induce
sustained control of simian-human immunodeficiency virus (SHIV) or simian …

Current approaches to reducing the latent HIV reservoir entail first reactivating virus-
containing cells to become visible to the immune system. A critical second step is killing …

HIV remission can be achieved in some people, called post-treatment HIV controllers, after
antiretroviral treatment discontinuation. Treatment initiation close to the time of infection was …

Combination antiretroviral therapy (ART) to treat human immunodeficiency virus (HIV)
infection has proven remarkably successful–for those who can access and afford it–yet HIV …

Elite controllers are a heterogeneous group of people living with HIV who control viral
replication without antiretroviral therapy. There is substantial evidence that at least some …

The human immunodeficiency virus (HIV) infection of the immune cells expressing the
cluster of differentiation 4 cell surface glycoprotein (CD4+ cells) causes progressive decline …

Following the success of HIV-1 antiviral treatment that maintains undetectable levels of viral
replication and lack of clinical progression, the design of an HIV-1 cure for patients became …